Search Results

30 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2013, Seville, ST 22

    The statistical benefit of performing GLP bioanalysis using assays that have reduced variability

    FARMEN R.H.; NEWLAND K.E.; GRAFF D.W.; COMBS M.L.
    Celerion, Lincoln, NE, U.S.A.; Celerion, Zürich, Switzerland
    Since the tobacco industry is moving into the area of regulated bioanalysis, we have noted that there is confusion surrounding the type of regulatory standards required for analytical methods to be used for testing tobacco constituents and biomarkers...
  2. TSRC, Tob. Sci. Res. Conf., 2013, 67, abstr. 34

    Development and validation of a bioanalytical assay to selectively quantitate aromatic amines (4-aminobiphenyl, o-toluidine, 1-aminonaphthalene, and 2-aminonaphthalene).

    NEWLAND K.; LAPKO V.; DZERK A.; NACHI R.
    Celerion, Lincoln, NE, USA
    new bioanalytical assay has been developed and validated that provides improved sensitivity, reproducibility, and selectivity for the analysis of total aromatic amines exposure. The determination of aromatic amines exposure has been identified as an...
  3. TSRC, Tob. Sci. Res. Conf., 2011, 65, abstr. 11

    An inter-laboratory comparison of urinary 3-hydroxypropylmercapturic acid measurement demonstrates good reproducibility between laboratories.

    CHEUNG F.(1); MINET E.(1); ERRINGTON G.(1); MCEWAN M.(1); SCHERER G.(2); NEWLAND K.(3); SHARIFI M.(4); BAILEY B.(5)
    (1) British American Tobacco, Group R&D, Southampton, UK; (2) ABF GmbH; (3) Celerion; (4) Labstat International Inc.; (5). Covance Laboratories Ltd.
    Background - Biomarkers have been used extensively in clinical studies to assess toxicant exposure in smokers and non-smokers and have recently been used in the evaluation of novel tobacco products. The urinary metabolite 3-HPMA, a metabolite of the...